DBV Technologies S.A. (NASDAQ:DBVT) had its price objective raised by Deutsche Bank AG from $46.00 to $56.00 in a report released on Sunday. Deutsche Bank AG’s price objective indicates a potential upside of 16.86% from the company’s current price.

A number of other research firms also recently commented on DBVT. BidaskClub cut shares of DBV Technologies from a “buy” rating to a “hold” rating in a research note on Friday, August 11th. Morgan Stanley reiterated an “overweight” rating and set a $72.00 price target (up previously from $70.00) on shares of DBV Technologies in a research note on Friday. Zacks Investment Research cut shares of DBV Technologies from a “buy” rating to a “hold” rating in a research note on Thursday, August 31st. Jefferies Group LLC reiterated a “buy” rating and set a $51.00 price target on shares of DBV Technologies in a research note on Tuesday, September 12th. Finally, Citigroup Inc. increased their price target on shares of DBV Technologies from $43.00 to $57.00 and gave the stock a “buy” rating in a research note on Monday, October 2nd. One research analyst has rated the stock with a sell rating, one has issued a hold rating and nine have issued a buy rating to the company’s stock. DBV Technologies presently has an average rating of “Buy” and an average target price of $56.29.

Shares of DBV Technologies (NASDAQ:DBVT) traded up 3.79% on Friday, reaching $47.92. The company had a trading volume of 288,699 shares. DBV Technologies has a 52 week low of $31.87 and a 52 week high of $48.11. The stock’s 50 day moving average is $43.87 and its 200 day moving average is $38.53. The firm’s market capitalization is $2.20 billion.

TRADEMARK VIOLATION WARNING: This report was reported by Watch List News and is the property of of Watch List News. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be viewed at https://www.watchlistnews.com/dbv-technologies-s-a-dbvt-price-target-raised-to-56-00/1618137.html.

Large investors have recently bought and sold shares of the business. Dynamic Technology Lab Private Ltd purchased a new position in DBV Technologies during the 2nd quarter valued at about $222,000. Victory Capital Management Inc. purchased a new position in DBV Technologies during the 1st quarter valued at about $303,000. Airain ltd purchased a new position in DBV Technologies during the 2nd quarter valued at about $333,000. Sit Investment Associates Inc. purchased a new position in DBV Technologies during the 2nd quarter valued at about $698,000. Finally, Jane Street Group LLC purchased a new position in DBV Technologies during the 1st quarter valued at about $853,000. Hedge funds and other institutional investors own 45.52% of the company’s stock.

DBV Technologies Company Profile

DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin.

Analyst Recommendations for DBV Technologies (NASDAQ:DBVT)

Receive News & Ratings for DBV Technologies S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies S.A. and related companies with Analyst Ratings Network's FREE daily email newsletter.